[Retracted] Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function

Table 1

Comparison of baseline data.

Indices	Control group ()	Dapagliflozin group ()	/ value	value
Age (years, )			0.85	0.36
Gender (male, , %)	27 (80.00)	26 (85.72)	0.14	0.66
BMI (kg/m^2, )			0.58	0.43
Duration of diabetes mellitus (years, )			0.42	0.52
Combined insulin (, %)	5 (16.59)	7 (23.40)	0.43	0.51
Oral hypoglycemic drugs (, %)
Metformin	11 (35.48)	12 (38.50)	0.08	0.76
Sulfonylurea	12 (39.60)	10 (29.20)	0.28	0.58
Alpha-glucosidase inhibitors	7 (22.90)	9 (29.00)	0.34	0.57
DPP4 inhibitors	8 (25.87)	6 (10.50)	0.36	0.55
Coronary heart disease drugs (, %)
Antiplatelet agents	30 (100.00)	30 (100.00)	0.01	1.05
Statin	29 (68.40)	27 (70.80)	0.23	0.62
Beta-blockers	13 (42.50)	16 (50.40)	0.58	0.42
ACEI/ARB	14 (68.50)	12 (38.66)	0.28	0.62